{"nctId":"NCT01419717","briefTitle":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","startDateStruct":{"date":"2011-11-22","type":"ACTUAL"},"conditions":["Bone Metastases in Men With Hormone-Refractory Prostate Cancer","Bone Metastases in Subjects With Advanced Breast Cancer"],"count":129,"armGroups":[{"label":"Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":["Xgeva"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject was previously enrolled in a denosumab phase 3 study and participated in the Open-label Extension portion of that study.\n* Subject or subject's legally acceptable representative has provided informed consent.\n\nExclusion Criteria:\n\n* Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment.\n* Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception during treatment and for 7 months after the end of treatment.\n* Subject has known sensitivity to any of the products to be administered during dosing.\n* Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge.\n* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment.\n\nEach AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-denosumab Binding Antibodies","description":"A blood sample was collected at the end of study visit for the measurement of anti-denosumab binding antibodies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":128},"commonTop":["Back pain","Nausea","Asthenia","Arthralgia","Decreased appetite"]}}}